Press release
Hypertension Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Hypertension Pipeline. Dive into DelveInsight's comprehensive report today! @ Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hypertension Pipeline Report
* In April 2025, Janssen Pharmaceuticals KK announced phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients (>=3 Months to
* In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
* DelveInsight's Hypertension pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
* The leading Hypertension Companies such as Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Promising Hypertension Pipeline Therapies such as Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
Stay ahead with the most recent pipeline outlook for Hypertension. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hypertension Treatment Drugs [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypertension Emerging Drugs Profile
* Seralutinib: Gossamer Bio
Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFR and PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.
* AD-209: Addpharma Inc.
AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.
* Zilebesiran: Alnylam Therapeutics
Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.
* LAM-001: ORPHAI THERAPEUTICS
LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.
* HS135: 35Pharma Inc.
HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.
The Hypertension Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
* Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market
Explore groundbreaking therapies and clinical trials in the Hypertension Pipeline. Access DelveInsight's detailed report now! @ New Hypertension Drugs [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypertension Companies
Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
Hypertension Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hypertension Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Hypertension Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hypertension Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hypertension Pipeline Report
* Coverage- Global
* Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
* Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hypertension Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hypertension Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Seralutinib: Gossamer Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Zilebesiran: Alnylam Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HS135: 35Pharma Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hypertension Key Companies
* Hypertension Key Products
* Hypertension- Unmet Needs
* Hypertension- Market Drivers and Barriers
* Hypertension- Future Perspectives and Conclusion
* Hypertension Analyst Views
* Hypertension Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertension-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3959423 • Views: …
More Releases from ABNewswire
WIJEOCHK LTD Announces Significant Expansion Progress in Iran as Magnet Media Ga …
Image: https://www.abnewswire.com/upload/2025/11/f97ad00c04e2651e6487d76f75dbc944.jpg
WIJEOCHK LTD, an international media and digital advertising technology company, today announced substantial progress in its expansion efforts within the Iranian market. This development marks a pivotal step forward for the Magnet Media platform in the Middle East, reflecting growing user demand in Iran for an efficient, reliable, and sustainable revenue-generating digital ecosystem.
According to internal performance data from WIJEOCHK LTD, Magnet Media has experienced strong user growth since its…
Kyle-Based Contractor Reports Surge in Bathroom Remodeling Projects as Homeowner …
Unicus Construction, LLC, in Kyle, TX, reports increased demand for home renovation services, particularly for kitchen and bathroom projects, as homeowners prioritize upgrades over relocation.
Kyle, TX residents are investing more in home improvements, with bathroom remodeling [https://maps.app.goo.gl/JJhfMbFYgPfBepkK8]emerging as one of the most requested services among local homeowners. Unicus Construction, LLC, a full-service renovation company based at 188 Rieber Road in Kyle, has experienced significant growth in project inquiries as more…
Family Dentist in Wenatchee Transforms Patient Experience with Compassionate Car …
Echo Ridge Dental in Wenatchee provides compassionate, accessible dental care with modern conveniences, including emergency video consultations and comprehensive accessibility features, for all patients.
A dental practice in Wenatchee is transforming the way families approach oral healthcare by combining cutting-edge accessibility features with personalized, compassionate care. Echo Ridge Dental [http://www.echoridge.dental/], led by Dr. Michael Potter, has established a reputation for creating memorable patient experiences that prioritize comfort and convenience. Located at…
Revelation Glass Pool Fences and Railings Transforms Pool Safety Standards with …
Revelation Glass Pool Fences and Railings offers premium frameless glass pool barriers and railing systems across DFW, combining safety compliance with modern aesthetics for residential and commercial properties.
Pool safety remains a critical concern for property owners across North Texas, with backyard drowning incidents continuing to rank among the leading causes of accidental death for children under five. Revelation Glass Pool Fences and Railings [https://www.revelationglassfence.com/] has positioned itself at the forefront…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
